Most cited papers from Group of Eight

Group of Eight

What are the most cited papers from Group of Eight?

The most cited paper from Group of Eight is "FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review" (Paz J. Vellanki, Flora A. Mulkey, Adnan A. Jaigirdar et al., 2021), with 58 citations. Next come "Prophylactic Antibiotics to Prevent Surgical Site Infection After Breast Cancer Surgery" (32) and "Measurement of Anticomplementary Activity in Therapeutic Intravenous Immunoglobulin Preparations" (16).

Published TypeFieldAccess

Showing 15 of 15 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review Paz J. Vellanki, Flora A. Mulkey, Adnan A. Jaigirdar et al. · Clinical Cancer Research Open access	25 Feb 2021	58
2	Prophylactic Antibiotics to Prevent Surgical Site Infection After Breast Cancer Surgery Denise Blanchard · Clinical journal of oncology nursing	Oct 2015	32
3	Measurement of Anticomplementary Activity in Therapeutic Intravenous Immunoglobulin Preparations Indra Ramasamy, Em Tran, Albert Farrugia · Biologicals	Mar 1997	16
4	A practical treatment for COVID ‐19 and the next pandemic Jahar Bhattacharya, Robert Booy, Arturo Casadevall et al. · Pharmacology Research & Perspectives Open access	15 Jul 2022	11
5	The Role of Elite Universities in National Higher Education and Research Systems, and the Challenges of Prosecuting the Case for Concentrating Public Investment in their Development in Australia Michael Sean Gallagher · SensePublishers eBooks Book chapter	2011	11
6	The incubation period in sterility testing. H Bathgate, D Lazzari, H Cameron et al. · PubMed	26 Jan 1994	10
7	Developing Spatial Microsimulation Estimates of Small Area Advantage and Disadvantage among Older Australians Honge Gong, Justine M. McNamara, Yogi Vidyattama et al. · Population Space and Place	13 Sep 2011	9
8	The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities Eduardo Agostinho Freitas Fernandes et al. · Journal of Pharmacy & Pharmaceutical Sciences Open access	21 Mar 2024	8
9	Microbial limits reviewed: the basis for unique Australian regulatory requirements for microbial quality of non-sterile pharmaceuticals. Shuzhu Tang · PubMed	26 Aug 1998	8
10	Cell culture influenza vaccine: an Australian perspective. Lung Chang, Robert R. Crichton, P. Nandapalan · PubMed	1999	3
11	Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia Thuy Phuong Nguyen, Lucy Dawes, Yuanfei Anny Huang et al. · The Lancet Regional Health - Western Pacific Open access	26 Feb 2025	2
12	Surveillance of adverse events following immunisation in Australia, 2023 Thuy Nguyen, Belinda Jones, Megan Hickie et al. · Communicable Diseases Intelligence Open access	28 Apr 2026	1
13	Decolonizing Conservation and the Importance of Nature‐Based Approaches, Not Solutions: Learning From Indigenous and Local Conservation Systems in India to Achieve the Global Biodiversity Agenda Garima Gupta, Isabel L. Jones, Achili Mihu et al. · Conservation Letters Open access	May 2026	0
14	Proceedings of the inaugural symposium on dengue human challenge studies “Challenging the norm: Accelerating dengue countermeasures through human studies” Shirin Kalimuddin, Adam Tully Waickman, Panisadee Avirutnan et al. · PLoS neglected tropical diseases Open access	9 Jan 2026	0
15	61MO Perceptions of healthcare professionals and regulators on the use of real-world data as external comparators in late-stage oncology single-arm trials Diogo Alexandre Martins-Branco, Douwe Postmus, Tarec Christoffer E El-Galaly et al. · ESMO Open Open access	Mar 2025	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.